Desjardins Global Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Desjardins Global Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.46M	Sell	6,036 -394	-6%	-$146K	0.26%	80
2023 Q3	$2.24M	Buy	6,430 +4,001	+165%	+$1.4M	0.24%	82
2023 Q2	$855K	Buy	2,429 +436	+22%	+$147K	0.1%	206
2023 Q1	$627K	Sell	1,993 -4,357	-69%	-$1.31M	0.08%	214
2022 Q4	$1.83M	Sell	6,350 -423	-6%	-$129K	0.29%	71
2022 Q3	$1.96M	Sell	6,773 -1,446	-18%	-$416K	0.25%	80
2022 Q2	$2.31M	Buy	8,219 +7,417	+925%	+$1.99M	0.3%	73
2022 Q1	$209K	Sell	802 -48	-6%	-$11.4K	0.02%	353
2021 Q4	$186K	Buy	+850	New	+$165K	0.02%	370

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Desjardins Global Asset Management's VRTX Position: Q4 2023 in Review

Desjardins Global Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 6.1% in Q4 2023, selling an estimated $146K and leaving 6,036 shares worth $2.46M. The position accounts for 0.26% of the portfolio, ranked #80.

Desjardins Global Asset Management first reported a position in VRTX in Q4 2021 and has held it in 9 quarters since. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Desjardins Global Asset Management held 6,036 shares of Vertex Pharmaceuticals worth $2.46M as of Q4 2023.
Desjardins Global Asset Management sold 394 Vertex Pharmaceuticals shares in Q4 2023, an estimated $146K.
Vertex Pharmaceuticals made up 0.26% of Desjardins Global Asset Management's portfolio in Q4 2023, its #80 holding.
Desjardins Global Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.